Epigenetic mechanisms — heritable changes in gene expression without alterations to the DNA sequence — have emerged as critical players across neurodegenerative diseases. These mechanisms include DNA methylation, histone modifications, chromatin remodeling, non-coding RNA regulation, and RNA modifications. The dynamic and potentially reversible nature of epigenetic modifications makes them attractive therapeutic targets across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD) .
This comparison examines how epigenetic dysregulation manifests across each disease and identifies shared versus disease-specific therapeutic approaches.
| Epigenetic Mechanism |
Alzheimer's Disease |
Parkinson's Disease |
ALS |
FTD |
Huntington's Disease |
| Global DNA Methylation |
Reduced (global hypomethylation) |
Variable, gene-specific |
Reduced |
Reduced |
Reduced globally |
| Gene-Specific Methylation |
ANK1, BIN1 hypermethylated |
SNCA intron 1 hypomethylation |
C9orf72 promoter |
GRN, TARDBP |
HTT promoter altered |
| Histone Acetylation |
Increased H3, H4 |
Altered H3/H4 |
Decreased globally |
Decreased |
Decreased H3/H4 |
| Histone Methylation |
Altered H3K4me3, H3K27me3 |
Altered marks |
H3K27ac loss |
H3K27ac loss |
H3K27me3 changes |
| HDAC Expression |
HDAC2 increased |
HDAC5 altered |
HDAC1-6 altered |
HDAC changes |
SIRT1 decreased |
| Epigenetic Age Acceleration |
+3-6 years |
+2-4 years |
+3-8 years |
+2-5 years |
+3-7 years |
| Chromatin Remodeling |
SWI/SNF altered |
ATP-dependent changes |
NuRD complex affected |
N/A |
Altered |
| Non-coding RNA |
miR-132, miR-124 altered |
miR-7, miR-153 altered |
miR-9, miR-124 altered |
miR-132 altered |
miR-9, miR-29 altered |
flowchart TD
subgraph Environmental_Exposures
ENV["Environmental Factors"]
TOX["Toxins/Pesticides"]
DIET["Diet"]
EXER["Exercise"]
STRESS["Stress"]
end
subgraph Genetic_Risk
GENE["Genetic Variants"]
MUT["Disease Mutations"]
GWAS["GWAS Loci"]
end
subgraph Epigenetic_Machinery
DNMT["DNA Methyltransferases"]
HAT["Histone Acetyltransferases"]
HDAC["Histone Deacetylases"]
HM["Histone Methyltransferases"]
end
subgraph Epigenetic_Marks
METH["5mC Methylation"]
ACHIST["Histone Acetylation"]
METHIST["Histone Methylation"]
CHROM["Chromatin State"]
end
ENV --> DNMT
TOX --> DNMT
DIET --> HAT
EXER --> HAT
GENE --> HM
MUT --> HM
GWAS --> HM
DNMT --> METH
HAT --> ACHIST
HM --> METHIST
METH --> CHROM
ACHIST --> CHROM
METHIST --> CHROM
CHROM --> GEXP["Gene Expression"]
subgraph Disease_Pathology
AD["Alzheimer's"]
PD["Parkinson's"]
ALS["ALS"]
FTD["FTD"]
HD["Huntington's"]
end
GEXP --> AD
GEXP --> PD
GEXP --> ALS
GEXP --> FTD
GEXP --> HD
classDef disease fill:#f3e5f5,stroke:#333,stroke-width:2px
classDef mechanism fill:#e1f5fe,stroke:#333,stroke-width:2px
classDef marks fill:#fff9c4,stroke:#333,stroke-width:2px
classDef enzyme fill:#c8e6c9,stroke:#333,stroke-width:2px
DNA methylation is the most studied epigenetic modification in AD. Genome-wide studies have identified widespread DNA methylation changes in AD brain and blood tissue. Key findings include:
- ANK1 hypermethylation in AD brain — associated with tau pathology
- BIN1 methylation changes — affects tau-mediated neurotoxicity
- Global hypomethylation in later disease stages
- Tau-driven methylation changes — Guo et al. demonstrated tau induces genome-wide promoter DNA methylation changes
The DNA methylation age (epigenetic clock) is accelerated by 3-6 years in AD brains compared to chronological age .
PD shows both global and gene-specific DNA methylation changes:
- SNCA intron 1 hypomethylation — increases alpha-synuclein expression
- PINK1 promoter methylation — affects mitophagy regulation
- PARK7 (DJ-1) methylation changes
- Global methylation variable depending on disease stage
Environmental factors significantly modify PD risk through epigenetic mechanisms:
- Pesticide exposure alters DNA methylation patterns in dopaminergic neurons
- Exercise may reverse some methylation changes
- Mediterranean diet associated with protective methylation patterns
ALS demonstrates widespread DNA methylation alterations:
- C9orf72 promoter methylation — correlates with hexanucleotide repeat expansions
- SOD1 promoter methylation status affects expression
- Global methylation reduced in motor cortex
- Accelerated epigenetic aging documented (+3-8 years)
The interface between genetic mutations and epigenetic dysregulation is particularly important in ALS, as mutant proteins directly affect epigenetic machinery.
FTD shows distinctive methylation patterns:
- GRN (progranulin) promoter methylation — affects expression in some cases
- TARDBP methylation changes (in TDP-43 proteinopathy)
- Global hypomethylation observed
- C9orf72 repeat expansion carriers show distinct methylation signatures
TDP-43 pathology directly affects expression of DNA repair and epigenetic regulatory genes.
HD exhibits unique epigenetic involvement:
- HTT promoter methylation status may affect expression
- Somatic CAG repeat expansion affected by MSH3 (DNA mismatch repair modifier)
- Global hypomethylation in affected brain regions
- Epigenetic age acceleration of 3-7 years
The DNA repair gene MSH3 is a major disease modifier in HD, linking epigenetic mechanisms to disease progression.
Histone acetylation alterations in AD:
- Increased histone H3 acetylation in hippocampus and temporal cortex
- Altered H3K4me3 (activating mark) at synaptic plasticity genes
- H3K27me3 (repressive mark) changes at memory-related genes
- HDAC2 increased — correlates with memory deficits
- HDAC inhibition improves memory in mouse models
Histone modification changes in PD:
- Decreased H3 acetylation at dopaminergic genes
- Altered H3K27me3 at SNCA locus
- HDAC5 alterations affect neuronal resilience
- SIRT1 activity may be protective
Histone deacetylases (HDACs) are major therapeutic targets, with SIRT1 activation showing neuroprotective effects.
ALS shows widespread histone changes:
- Global histone hypoacetylation in motor cortex
- H3K27ac loss at gene activation sites
- HDAC1-6 alterations — therapeutic targets
- FUS (FUS) interacts with histone modifying complexes
- TDP-43 pathology affects chromatin regulation
HDAC inhibitors are in preclinical investigation for ALS.
FTD histone modifications:
- H3K27ac loss similar to ALS
- Chromatin accessibility reduced in frontotemporal regions
- HDAC changes throughout disease
- TDP-43-associated epigenetic dysregulation
HD histone alterations:
- Decreased histone acetylation at neuronal genes
- H3K27me3 changes affect transcription
- SIRT1 decreased in affected regions
- HDAC inhibitor benefits in preclinical models
HDAC inhibition represents a therapeutic approach in development.
| Target |
Strategy |
Disease Relevance |
| DNMT inhibitors |
5-azacytidine, decitabine |
PD (SNCA), research phase |
| HDAC inhibitors |
TSA, SAHA, valproic acid |
AD, HD, ALS |
| HAT activators |
CBP/p300 activation |
AD, HD |
| SIRT1 modulators |
Resveratrol, SRT2104 |
AD, PD, HD |
| EZH2 inhibitors |
Tazemetostat |
Research phase |
| Bromodomain inhibitors |
JQ1, OTX015 |
Research phase |
- Alzheimer's Disease: HDAC2 inhibition, HAT activation, DNA methylation modulators
- Parkinson's Disease: SNCA methylation modulators, SIRT1 activators, environmental epigenetics
- ALS: HDAC inhibitors, FUS-targeted approaches, C9orf72 methylation
- FTD: TDP-43 targeted approaches, GRN modulation
- Huntington's Disease: HDAC inhibitors, MSH3 targeting, somatic expansion blockers
| Trial ID |
Intervention |
Target |
Status |
Disease |
| NCT00001742 |
Valproic acid |
HDAC |
Completed |
AD |
| NCT00261833 |
Sodium butyrate |
HDAC |
Completed |
HD |
| NCT00145252 |
Resveratrol |
SIRT1 |
Completed |
AD |
| NCT04425382 |
Tazemetostat |
EZH2 |
Recruiting |
FTD |
Epigenetic biomarkers under development:
- Blood DNA methylation signatures for early detection
- Epigenetic age acceleration as progression marker
- miRNA profiles for disease stratification
- Histone modification signatures in cerebrospinal fluid
- SNCA — Alpha-synuclein, PD methylation target
- PINK1 — Mitophagy, PD methylation
- PARK7 — DJ-1, PD
- LRRK2 — Leucine-rich repeat kinase 2
- C9orf72 — ALS/FTD hexanucleotide repeat
- GRN — Progranulin, FTD
- TARDBP — TDP-43, ALS/FTD
- SOD1 — ALS mutations
- HTT — Huntingtin
- HDAC2 — Therapeutic target
- SIRT1 — Therapeutic target